Health & Medicine Archives - Page 296 of 305

Alleged Cover-up Could Blow Roof off of Asbestos Litigation

Staff - September 5, 2015

The appeals ruling involved a class-action suit filed by relatives of alleged asbestos victims who accused BASF and Cahill of a systematic cover-up involving the destruction of key documents involving Engelhard asbestos litigation. Although the case in itself is not injury related, evidence of a cover-up could revive many previously litigated cases and cases in which plaintiffs settled for less than they would have had they attained access to factual information.

Sincerely Nuts Recalls Macadamia Products due to Salmonella Scare

Staff - September 5, 2015

According to the FDA, Persons infected with the salmonella organism “often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain” that in rare circumstances, “can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.”

Appeals Court Rules for Novartis against Amgen in Biosimilar Cancer Treatment Suit

Staff - September 3, 2015

The U.S. Court of Appeals for the Federal Circuit granted a major victory for Novartis AG, the world’s pharmaceutical market leader. The court’s three-judge panel ruled 2-1 on Wednesday, declining a petition to renew a six-month injunction filed by competitor Amgen involving the marketing of a biosimilar drug comparable to Amgen’s breakthrough cancer treatment Neupogen

Valeant Strikes Collaboration Deal with AstraZeneca over Experimental Psoriasis Drug

Staff - September 1, 2015

The terms of the agreement include Valeant paying AstraZeneca $100 million up front, adding another $170 million depending on pre-launch benchmarks, as well as up to $175 million depending upon sales benchmarks. After the product’s launch, the two companies will share profits. Valeant will handle the regulatory submission processes and the associated costs. In return, Valeant will retain the commercialization rights to brodalumab in all markets except in Japan and some Asian countries, where Amgen, the originator of the drug, had made a pre-existing agreement with Japanese biotech firm Kyowa Hakko Kirin.

Marcy Borders, 9/11 ‘Dust Lady,’ Dies of Cancer at 42

Staff - August 27, 2015

Borders’s death is a stark reminder that many of those who endured the 9/11 tragedy are suffering from long-term health problems. Borders was asked if she thought that the debris from the terror attack, which contained glass and other carcinogenic dust, among other dangerous particles led to her cancer. She responded, “I’m saying to myself, ‘Did this thing ignite cancer cells in me?’ I definitely believe it because I haven’t had any illnesses. I don’t have high blood pressure, high cholesterol, diabetes.”

Judge Dismisses Part of Plavix Multidistrict False Claims Lawsuit

Staff - August 25, 2015

Judge Freda Wolfson of the U.S. District of New Jersey has granted some relief for drugmakers Bristol-Myers Squibb and Sanofi-Aventis in a complicated multidistrict whistleblower lawsuit against the two companies over marketing claims involving the blood-thinning medication Plavix. Wolfson granted motions to dismiss several claims made by former Sanofi sales representative Elisa Dickson, alleging that

FTC Urges FDA to Re-evaluate Homeopathic Product Regulation

Staff - August 25, 2015

The $3 billion industry has increasingly drawn the attention of both regulators. Among the questions the FDA brought up in the request for comment involve consumer and health provider attitudes towards homeopathic products, requests for data sources regarding the safety of the products, and what kind of measures could be implemented to improve the clarity of the CPG’s standard, among others.

GSK Sells Rights to Autoimmune Drug to Novartis for up to $1 Billion

Staff - August 23, 2015

While the timing of the purchase is ideal in many respects for Novartis considering its portfolio and the pending loss of the gilenya patent, it is also timing that has some in the industry questioning the deal. Ocrelizumab is about two years ahead in development compared to ofatumumab, having completed two successful late-stage studies in June.

Appeals Court Rules in Favor of Labor Department and Home Care Workers

Staff - August 22, 2015

Calling it a “tremendous victory,” Sarah Leberstein, senior staff attorney for the National Employment Law Group said, “Paying workers less than the minimum wage for their work hours, and not paying an overtime premium after 40 hours a week benefits no one.” According to the advocacy group Caring Across Generations, domestic care is one of the U.S.’s lowest paying industry, with an average hourly wage of $9.61.

Valeant Buys Sprout Pharmaceuticals, Maker of Just-Approved Female Libido Medication

Staff - August 20, 2015

Valeant’s purchase of Sprout will include $500 million cash up front as well as $500 million when the deal is closed, which is expected to be in early 2016. In addition, Valeant has agreed to give Sprout a portion of future revenues if certain milestones are met, although neither party would discuss specifics. Sprout CEO Cindy Whitehead will join Valeant and lead the division responsible for Addyi.

Health & Medicine

Trending